BlackRock’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$192M Buy
10,684,103
+364,934
+4% +$5.1M ﹤0.01% 1825
2026
Q1
$97.2M Sell
10,319,169
-28,557
-0.3% -$314K ﹤0.01% 2127
2025
Q4
$129M Buy
10,347,726
+118,543
+1% +$1.58M ﹤0.01% 1942
2025
Q3
$147M Sell
10,229,183
-122,569
-1% -$1.68M ﹤0.01% 1851
2025
Q2
$127M Sell
10,351,752
-387,291
-4% -$5.62M ﹤0.01% 1892
2025
Q1
$236M Sell
10,739,043
-389,347
-3% -$9.16M 0.01% 1498
2024
Q4
$252M Buy
11,128,390
+242,167
+2% +$5.29M 0.01% 1534
2024
Q3
$198M Sell
10,886,223
-367,181
-3% -$8.51M ﹤0.01% 1666
2024
Q2
$328M Buy
11,253,404
+4,605,646
+69% +$137M 0.01% 1288
2024
Q1
$236M Buy
6,647,758
+5,913
+0.1% +$236K 0.01% 1539
2023
Q4
$289M Sell
6,641,845
-192,342
-3% -$7.57M 0.01% 1393
2023
Q3
$261M Buy
6,834,187
+58,738
+0.9% +$2.47M 0.01% 1365
2023
Q2
$279M Sell
6,775,449
-237,386
-3% -$11.4M 0.01% 1346
2023
Q1
$403M Sell
7,012,835
-130,401
-2% -$7.35M 0.01% 1057
2022
Q4
$401M Sell
7,143,236
-45
-0% -$2.29K 0.01% 1034
2022
Q3
$303M Buy
7,143,281
+442,760
+7% +$22.7M 0.01% 1165
2022
Q2
$362M Sell
6,700,521
-47,135
-0.7% -$2.83M 0.01% 1094
2022
Q1
$434M Sell
6,747,656
-11,836
-0.2% -$779K 0.01% 1087
2021
Q4
$453M Buy
6,759,492
+111,789
+2% +$7.56M 0.01% 1102
2021
Q3
$455M Buy
6,647,703
+28,549
+0.4% +$2.02M 0.01% 1056
2021
Q2
$452M Buy
6,619,154
+82,154
+1% +$5.81M 0.01% 1094
2021
Q1
$452M Buy
6,537,000
+113,989
+2% +$7.72M 0.01% 1089
2020
Q4
$417M Buy
6,423,011
+10,249
+0.2% +$552K 0.01% 1028
2020
Q3
$303M Sell
6,412,762
-117,043
-2% -$5.57M 0.01% 1068
2020
Q2
$307M Sell
6,529,805
-16,543
-0.3% -$813K 0.01% 1038
2020
Q1
$292M Sell
6,546,348
-121,678
-2% -$6.39M 0.01% 901
2019
Q4
$389M Buy
6,668,026
+102,434
+2% +$6.1M 0.01% 994
2019
Q3
$394M Sell
6,565,592
-87,479
-1% -$5.21M 0.02% 916
2019
Q2
$372M Sell
6,653,071
-34,627
-0.5% -$1.78M 0.02% 974
2019
Q1
$373M Sell
6,687,698
-42,606
-0.6% -$2.17M 0.02% 940
2018
Q4
$304M Buy
6,730,304
+210,960
+3% +$11.6M 0.02% 999
2018
Q3
$429M Buy
6,519,344
+107,781
+2% +$6.7M 0.02% 851
2018
Q2
$413M Sell
6,411,563
-1,959,748
-23% -$121M 0.02% 862
2018
Q1
$463M Buy
8,371,311
+235,759
+3% +$12.4M 0.02% 747
2017
Q4
$389M Buy
8,135,552
+269,484
+3% +$13.2M 0.02% 861
2017
Q3
$397M Buy
7,866,068
+469,167
+6% +$24.1M 0.02% 808
2017
Q2
$403M Sell
7,396,901
-58,663
-0.8% -$2.8M 0.02% 770
2017
Q1
$314M Buy
7,455,564
+7,450,720
+153,813% +$318M 0.02% 931
2016
Q4
$208K Sell
4,844
-788
-14% -$32K ﹤0.01% 2120
2016
Q3
$232K Buy
5,632
+454
+9% +$19K ﹤0.01% 2077
2016
Q2
$207K Buy
5,178
+1,146
+28% +$41.2K ﹤0.01% 2079
2016
Q1
$136K Buy
4,032
+2,332
+137% +$72.6K ﹤0.01% 1852
2015
Q4
$57K Sell
1,700
-398
-19% -$12.4K ﹤0.01% 1977
2015
Q3
$62K Buy
2,098
+469
+29% +$14.7K ﹤0.01% 1833
2015
Q2
$45K Sell
1,629
-62
-4% -$1.65K ﹤0.01% 2018
2015
Q1
$43K Hold
1,691
﹤0.01% 2016
2014
Q4
$37K Hold
1,691
﹤0.01% 2093
2014
Q3
$34K Hold
1,691
﹤0.01% 2094
2014
Q2
$32K Buy
1,691
+93
+6% +$1.73K ﹤0.01% 2136
2014
Q1
$30K Hold
1,598
﹤0.01% 2160
2013
Q4
$32K Hold
1,598
﹤0.01% 2119
2013
Q3
$27K Hold
1,598
﹤0.01% 2116
2013
Q2
$24K Buy
+1,598
New +$23.4K ﹤0.01% 2203

Other funds holding IART

BlackRock's IART Position: Q2 2026 in Review

BlackRock increased its Integra LifeSciences (IART) stake by 3.5% in Q2 2026, buying an estimated $5.1M and bringing the position to 10,684,103 shares worth $192M. The position accounts for ﹤0.01% of the portfolio, ranked #1825.

BlackRock first reported a position in IART in Q2 2013 and has held it in 53 quarters since. The position peaked at $463M in Q1 2018. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

  • BlackRock held 10,684,103 shares of Integra LifeSciences worth $192M as of Q2 2026.
  • BlackRock bought 364,934 Integra LifeSciences shares in Q2 2026, an estimated $5.1M.
  • Integra LifeSciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1825 holding.
  • BlackRock first reported a position in Integra LifeSciences in Q2 2013 and has held it in 53 quarters since.
  • BlackRock's Integra LifeSciences position peaked at $463M in Q1 2018.
  • 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.